Skip to main content

Clinical Pathways promote evidence based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by methodical review of available evidence and consensus among committee members.

Clinical Pathways:

Inclusion and exclusion criteria:

  • Inclusion:  
    • Patients requiring anticoagulation therapy or prophylaxis. 
  • Exclusion:  
    • Patients on ECMO, cardiac bypass pump, hemodialysis or continuous renal replacement therapy.  
    • Anticoagulation to maintain patency of arterial or central venous catheters. 

Committee members involved in the development:

  • Shannon Carpenter MD, MS | Hematology/Oncology/BMT | Committee chair 
  • Lauren Amos, MD | Hematology/Oncology/BMT | Committee member
  • Sara McElroy, MD | Hematology/Oncology/BMT Fellow | Committee member
  • Thomas Cochran, MD | Hematology/Oncology/BMT Fellow | Committee member
  • Michael Rose, PharmD | Pharmacy | Committee member
  • Todd Glenski, MD, MSHA, FASA | Anesthesiology, Evidence Based Practice
  • Jarrod Dusin, MS, RD, CPHQ | Evidence Based Practice
  • Kori Hess, PharmD | Evidence Based Practice

Publication dates:

  • Finalized date: 2016; 7/27/2018; 10/31/2019; 2/23/2022; 9/26/23; 11/20/23
  • Next expected revision date: 09/2026

If you have any questions regarding this content, or identify a broken link, please email 

These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.